3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Uterine Cervical Neoplasms
3
Prostatic Neoplasms
3
Urinary Bladder Neoplasms
2
Sarcoma
2
Pancreatic Neoplasms
2
Breast Neoplasms
2
Urologic Neoplasms
1
Urologic Diseases
1
Urogenital Neoplasms
1
Urogenital Diseases
1
Urinary Bladder Diseases
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma, Ewing
1
Prostate Adenocarcinoma
1
Neoplasms by Site
1
Neoplasms
1
Neoplasm Metastasis
1
Male Urogenital Diseases
1
Lymphedema
1
Lung Neoplasms
1
Gallbladder Neoplasms
1
Financial Stress
1
Female Urogenital Diseases
1
Endometrial Neoplasms
1
Encopresis
1
Cholangiocarcinoma
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Intraductal, Noninfiltrating
1
Breast Carcinoma In Situ
1
Interventions
pembrolizumab
3
Paclitaxel
2
Carboplatin
2
ulixertinib
1
trastuzumab deruxtecan
1
trastuzumab biosimilar HLX02
1
trametinib
1
selinexor
1
sapanisertib
1
relatlimab
1
pertuzumab
1
palbociclib
1
osimertinib
1
omipalisib
1
larotrectinib
1
ipatasertib
1
erdafitinib
1
dostarlimab
1
defactinib
1
dabrafenib
1
copanlisib
1
capivasertib
1
binimetinib
1
adavosertib
1
X-Rays
1
Vaginal Smears
1
VMBP protocol
1
Trastuzumab
1
Sutures
1
Sunitinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Uterine Neoplasms
×
Radiation Dose Hypofractionation
×
90 days
×
Clear all
No trials found.